Preoperative concurrent chemo- and endocrine therapies for women with large operable breast cancer expressing steroid hormone receptors
- 31 December 2008
- journal article
- Published by Elsevier in The Breast
- Vol. 17 (6) , 654-660
- https://doi.org/10.1016/j.breast.2008.05.002
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancerCancer, 2007
- Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer PatientsJournal of Clinical Oncology, 2006
- Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An UpdateJournal of Clinical Oncology, 2006
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Adjuvant chemo-endocrine therapy for breast cancer: Combined or sequential?The Breast, 2003
- Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With DocetaxelJournal of Clinical Oncology, 2002
- Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptorsAnnals of Oncology, 2000
- In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on cancer cell sensitivity to cis-platinumCancer Letters, 1998
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.Journal of Clinical Oncology, 1998
- Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST piBritish Journal of Cancer, 1996